Verzenios 50 mg film-coated tablets clinical trials
5 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
J1S-MC-JP04: A Randomized, Open-Label Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Relapsed or Refractory Ewing’s Sarcoma
This study is looking at a new way to treat Ewing's sarcoma that has come back or hasn’t responded to previous treatments. It uses a tablet called Verzenios (abemaciclib) along with two chemotherapy drugs, irinotecan and temozolomide. Researchers want to see how well this combination stops the cancer from growing.
For: Ewings SarcomaItaly · Spain · France - AuthorisedTherapeutic use (Phase IV)
DOSABEMA-Pharmacokinetic model of abemaciclib: correlation with severe diarrhea as the primary toxicity endpoint in patients with hormone receptor-positive localized breast cancer
This study looks at how a breast cancer drug, Verzenios, affects people's bodies and how this links to side effects like severe diarrhoea. It focuses on women with a specific type of breast cancer to understand the drug better and make treatment safer.
For: HER2- breast cancer at high risk of recurrenceFrance - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
I3Y-MC-JPCS: A Phase 1b/2 Study of Abemaciclib in Combination with Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors and Abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients with Relapsed/Refractory Neuroblastoma (Part C).
This study is testing a new medicine, abemaciclib, combined with other treatments for children and young adults with solid cancers that have come back or not responded to previous treatment. Researchers want to find the safest and most effective dose.
For: Relapsed/Refractory Solid TumorsSpain - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1 /2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of amcenestrant (SAR439859 ), administered orally as monotherapy, then in combination with other anti-cancer therapies in postmenopausal women with estrogen receptor-positive advanced breast cancer
This study looks at a new drug, amcenestrant, for postmenopausal women with advanced breast cancer. It tests its safety and how well it works, both alone and with other common cancer medicines.
For: CancerBelgium · Spain - AuthorisedTherapeutic use (Phase IV)
Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6 inhibitors. "The EX-AI study"
This study looks at how exercise affects the quality of life for women with early breast cancer. These women are taking hormone treatments, sometimes with another medicine called a CDK4/6 inhibitor. The study wants to see if exercise helps with symptoms and overall well-being.
For: Early Breast CancerSpain